Ixazomib (MLN-2238)

Product information

$120.00

Description

Description

Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.

Overview

Overview

Powder; no buffer, Souce: chemical synthesis, Buffer: Powder; no buffer

Additional details

Downloads

Downloads

http://www.ubpbio.com/temp/F1110%20F1111_Ixazomib%20(MLN-2238)_Datasheet.pdf

SKU

UBP-F1110

Manufacturer Part Number

F1110

UOM

5 mg